13.6 Trial Registration, Results Transparency & Communicating Results to Participants

Trial Registration, Results Transparency & Communicating Results to Participants

Quick Reference: ICH E6(R3) Principle 9.6 states that "the transparency of clinical trials includes timely registration on publicly accessible and recognised databases and the public posting of clinical trial results. Communicating trial results to participants should be considered. Such communication should be objective and non-promotional." Transparency is no longer a publication-ethics footnote — it is one of the eleven principles.

Why this is new, and why it is tested

E6(R2) contained no transparency principle. Registration and results posting lived in journal policy, national law and the Declaration of Helsinki, but not in GCP itself. E6(R3) changed that, which makes transparency exactly the kind of topic that generates fresh exam items: an experienced candidate reasoning from E6(R2) instincts will get it wrong.

The obligation also appears in the other reference document ACRP names — the Declaration of Helsinki, revised by the World Medical Association in October 2024.

---

Registration: before the first participant

Read the Helsinki wording carefully: the deadline is before recruitment of the first participant, not before the first participant is randomised, not before enrolment closes, and not at publication.

Why prospective registration matters

Registration before recruitment creates a public, timestamped record of what the trial said it would measure before anyone knew how it would turn out. That single fact defeats three distinct failure modes:

1. Publication bias — a trial that exists in a registry cannot silently disappear when its results disappoint.
2. Outcome switching — promoting a secondary endpoint to primary after seeing the data becomes visible, because the registered entry names the original primary endpoint.
3. Duplicate or wasteful research — investigators and funders can see what is already under way.

What a registration entry contains

• Sponsor, funder and responsible party
• Condition, intervention and comparator
• Study design, phase, allocation and masking
• Primary and secondary outcome measures, with time frames
• Key eligibility criteria
• Target sample size
• Recruitment status and locations
• Contact information

Exam Watchout: Registration is normally a sponsor responsibility, but the site is affected by it. Participants and their treating physicians consult registries, the registry record must match the approved protocol, and a mismatch between the registered primary endpoint and the protocol is a finding. Where a substantial amendment changes an endpoint or the design, the registry record must be updated, not left as first posted.

---

Results posting: including the results nobody wanted

The phrase "negative and inconclusive as well as positive" is the examinable part. The ethical argument is direct: participants accepted risk and burden on the understanding that their contribution would add to knowledge. Suppressing an unfavourable result breaks that bargain and, worse, leaves clinicians with a systematically distorted evidence base — the treatment looks better than it is because only the flattering trials were published.

Selective reporting as an integrity failure

Publishing only favourable outcomes, or reframing the analysis after seeing the data, is a research integrity failure of the same family as those in section 7.4. The controls are structural rather than moral:

Exam Watchout: A clinical trial agreement clause permitting the sponsor to delay publication for a defined, reasonable period to protect intellectual property is normal and acceptable. A clause permitting the sponsor to suppress publication, or to publish only if results are favourable, is not, and an investigator should not sign it.

---

Communicating results to participants

This is the newest and least familiar element. E6(R3) Principle 9.6 says communicating results to participants should be considered, and that any such communication "should be objective and non-promotional." ECO task statement 41 states it as an activity: "Inform study participants of study results, in accordance with regulatory requirements."

Note the calibration precisely, because the exam will test it: this is "should be considered" — a deliberate obligation to think about it and plan for it — not an absolute requirement to disseminate individually in every trial. What is not optional is the manner: objective and non-promotional.

Doing it well

Two distinct things participants ask for

1. "How did the trial turn out?" — aggregate results. Answered by the planned summary once available.
2. "Which arm was I in?" — individual unblinding. This is not released on request during the trial, and after the trial only per the protocol's provisions. A coordinator should never disclose arm assignment informally, and a participant asking mid-trial should be told, kindly, that the answer would compromise the trial and will be available in line with the plan described at consent.

Where a trial generates a clinically actionable individual finding — an incidental imaging finding, a genetic result the consent covered — return of that specific result follows the protocol's own pathway, which is separate from results dissemination.

---

Realistic exam scenario

Scenario: A three-year trial completes. The primary endpoint was not met; a secondary endpoint reached nominal significance. The sponsor's publication committee proposes to submit a manuscript titled around the secondary endpoint, to update the registry entry so the secondary endpoint is listed first, and to send participants a letter thanking them and stating that "the study showed encouraging benefits." A coordinator is asked to post the letter to her site's 42 participants.

Evaluation — four separate failures:

1. Reframing the manuscript around the secondary endpoint is outcome switching. The registered and protocol-specified primary endpoint was not met, and that must be reported as the trial's principal finding.
2. Retrospectively reordering the registry entry compounds it. Registry records are amended to reflect approved protocol changes made prospectively, not to reflect what the data later favoured.
3. "Encouraging benefits" is promotional, and E6(R3) Principle 9.6 requires participant communication to be objective and non-promotional. It is also inaccurate, since the trial's primary question was answered in the negative.
4. The letter has not been through IRB/IEC review and was not described to participants at consent.

Correct actions: the coordinator should decline to distribute the letter as drafted and escalate to the sponsor and the principal investigator. The primary endpoint result must be reported publicly regardless of its direction — Declaration of Helsinki paragraph 36 requires negative and inconclusive results to be made publicly available. The registry entry should reflect the endpoints as prospectively specified. Any participant-facing summary should be rewritten in plain, objective language stating that the trial did not meet its primary endpoint, describing the secondary finding with appropriate caution about its exploratory status, and thanking participants for a contribution that is valuable precisely because it produced a reliable answer. The revised summary goes to the IRB/IEC before it goes to participants.